< Back to previous page

Project

Drug delivery systems and in vivo efficacy of the serine protease inhibitor UAMC-00050 in a preclinical model for irritable bowel syndrome.

The serine protease inhibitor UAMC-00050, previously shown efficacious in 2 preclinical IBS models after systemic administration, will be formulated for oral and rectal administration. The drug delivery systems will be tested in the rat IBS model for dose determination, efficacy, time of administration and serum concentrations, a crucial step towards further valorization of the compound.
Date:1 Oct 2018 →  30 Sep 2019
Keywords:IRRITABLE BOWEL SYNDROME, SERINE PROTEASE INHIBITOR, VISCERAL PAIN
Disciplines:Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences